Ozempic and Bone Density: What Women Should Know

Semaglutide, the medicine in Ozempic and Wegovy, has not been shown to cause osteoporosis, but two findings matter for women. In the Wegovy heart-outcomes trial, hip and pelvis fractures were reported in 1% of women on Wegovy against 0.2% on placebo⁷. A small randomized trial also found lower hip and spine bone density after a year¹.

The trial that makes this worth a dedicated guide

Most GLP-1-and-bone coverage leans on reassurance: these drugs were not designed to touch bone, so surely they don't. A 2024 phase 2 randomized trial designed specifically to test that assumption found something more complicated. Sixty-four adults with an existing high fracture risk — 55 of them postmenopausal women — were randomized to once-weekly semaglutide or placebo for a year. At 52 weeks, the semaglutide group had measurably lower bone mineral density than placebo at both the lumbar spine and total hip, and a marker of bone breakdown (CTX) was higher in the semaglutide group too, even though a marker of new bone formation (PINP) did not differ between groups¹. Semaglutide also produced 6.8 kg more weight loss than placebo in the same trial. This is one small trial, not a verdict — but it is a real, randomized, women-majority result, and it is the reason this deserves more than a reassuring paragraph.

What the Wegovy label says about fractures in women

Wegovy is semaglutide, the same medicine as Ozempic, at a higher weekly dose for weight loss. Its label reports that in the large cardiovascular-outcomes trial, more hip and pelvis fractures occurred on Wegovy than on placebo in women, and in people 75 and older⁷:

In a separate Wegovy trial in adults with MASH, a fatty liver disease, fractures of any kind occurred in 4.4% on Wegovy and 3.3% on placebo, in both men and women⁷. The label reports these differences without assigning a cause. The Ozempic and Zepbound labels carry no comparable fracture finding, which reflects what their trials reported rather than proof that their bones fare better.

Why this lands harder on women specifically

None of this happens in a vacuum. Bone density in women falls fastest in the years right around menopause, as declining estrogen removes a hormone that had been protecting bone turnover for decades — a trajectory tracked in detail by longitudinal studies like the SWAN cohort, which followed bone density through the menopause transition using high-resolution imaging⁵ and a nine-year prospective study that measured the same accelerating loss through the perimenopausal years⁶. That baseline decline is already the largest bone-density risk factor most women will ever have. Layering a medication-associated BMD reduction on top of it — during the same years many women start a GLP-1 for menopausal weight change — is a genuinely different question than what the same trial would mean for a 35-year-old man, and it is the piece our guide to the perimenopause and menopause transition does not have room to cover in full.

What the broader evidence says

Zoom out and the picture gets more mixed, not more alarming. A narrative review of GLP-1 receptor agonists and bone health in people with obesity found the class has generally been neutral-to-favorable on fracture risk in larger, longer diabetes-outcome trials, even as mechanistic questions remain open². A 2025 critical appraisal of anti-obesity medications and bone metabolism reached a similar middle-ground conclusion: rapid, large-magnitude weight loss from any method — surgery, calorie restriction, or a GLP-1 — tends to reduce BMD somewhat, because bone remodels down along with fat and lean mass, and the open question is whether GLP-1s add anything beyond that expected weight-loss effect³. A smaller pilot analysis of older adults on GLP-1 receptor agonists found bone turnover changes but no dramatic density loss over 20 weeks⁴. Put plainly: this is not settled science, and a site that told you it was would be overstating what four years of data can support.

Who should have a bone-density scan?

Starting a GLP-1 is not, by itself, a universal instruction to obtain a baseline DXA. The 2025 USPSTF recommendation supports screening women aged 65 or older and postmenopausal women younger than 65 whose clinical risk assessment shows increased fracture risk⁸. This corrects the idea that every postmenopausal woman starting weight treatment automatically needs a scan.

Discuss prior fractures, family history, smoking, low body weight and other relevant medical or medication risks with the clinician. A person with known osteoporosis or a prior fragility fracture needs a management plan, not simply a screening checklist. The clinician should decide whether testing would change care and when another scan would be useful.

Exercise evidence is useful, but not a guarantee

A randomized-trial secondary analysis compared exercise, liraglutide, their combination and placebo after an initial low-calorie diet. The combination preserved bone health while supporting weight loss, whereas liraglutide alone reduced density at important sites more than exercise alone⁹. This is direct clinical evidence for considering physical activity alongside medication, but it studied liraglutide rather than proving a particular semaglutide or tirzepatide exercise program prevents fractures.

Ask for an activity plan suited to your balance, pain, fracture history and current abilities. Nutrition, fall risk and established osteoporosis treatment also belong in the discussion. Our muscle and strength guide explains why a body-composition result is different from a functional assessment.

Make bone health part of continuity of care

Tell a weight-management prescriber if another clinician manages osteoporosis or menopause hormone therapy. Ask who follows the bone-health plan and whether a change in weight, intake or mobility would lead to a review. A commercial package promising comprehensive labs is not evidence that an individual fracture-risk assessment has taken place.

If a fall or fracture leads to surgery, make the anesthesia team aware of the medicine and arrange a procedure-specific GLP-1 plan. For a longer trip, our travel and storage guide helps plan medication access without creating an unplanned treatment gap.

The trial signals merit attention, while the screening decision still depends on the patient. Neither a falling scan number nor a reassuring general statement about the drug class should replace that clinical assessment.

Hormone therapy is one of the few treatments that protects bone through menopause, and the fear that it adds weight is mostly unfounded; see hormone therapy and weight, by the numbers.

Bone is one of several side effects that play out differently in women; our hub on GLP-1 side effects in women covers the rest.